Quantcast

Latest Auxilium Pharmaceuticals Inc. Stories

2014-06-30 12:32:44

NEW YORK, June 30, 2014 /PRNewswire/ -- Levi & Korsinsky is investigating the Board of Directors of Auxilium Pharmaceuticals Inc. ("Auxilium" or "the Company") (NasdaqGS: AUXL) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to QLT Inc. (NasdaqGS: QLTI). http://photos.prnewswire.com/prnvar/20120409/MM84375LOGO Click here to learn more about the investigation: http://zlk.9nl.com/auxilium-pharmaceuticals-auxl, or...

2014-06-26 08:27:14

Accelerates Auxilium's Ongoing Transformation Into Leading North American Specialty Biopharmaceutical Company CHESTERBROOK, Pa. and VANCOUVER, Canada, June 26, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, and QLT Inc. (NASDAQ: QLTI) (TSX: QLT), a Canadian-based biotechnology company focused on developing innovative orphan ophthalmology products, today announced that they have entered into a definitive...

2014-06-25 16:26:44

LYNBROOK, N.Y., June 25, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, announced today that Swedish Orphan Biovitrum AB (Sobi) has filed for an extension of the label for XIAPEX (the EU trade name for collagenase clostridium histolyticum or CCH) with the European Medicines Agency (EMA) to include the indication of...

2014-06-25 08:31:00

STOCKHOLM and CHESTERBROOK, Pa., June 25, 2014 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. today announced that Sobi has filed for an extension of the label for Xiapex® (collagenase clostridium histolyticum) with the European Medicines Agency (EMA) to include the indication of Peyronie's disease. The filing is based on positive safety and efficacy outcome data from two double-blind placebo-controlled studies, IMPRESS I and II (The...

2014-06-11 08:28:34

CHESTERBROOK, Pa., June 11, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that it has partnered with Prasco, LLC ("Prasco") to introduce an Authorized Generic version of Testim(®) (testosterone gel). Prasco has product inventory available and has commenced shipping product. Testim and its Authorized Generic version are testosterone gels approved by the U.S. Food and Drug Administration to treat...

2014-06-02 16:26:58

CHESTERBROOK, Pa., June 2, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that James E. Fickenscher, Chief Financial Officer, is leaving the Company to pursue other interests. Mr. Fickenscher will continue in his current role through August 15, 2014. "The Board and I want to thank Jim for his nine years of service and important contributions to the evolution of Auxilium," said Adrian Adams,...

2014-05-30 08:25:45

CHESTERBROOK, Pa., May 30, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Jefferies Healthcare Conference to be held June 2-5, 2014 in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio Company at 10:00 a.m. ET on Tuesday, June...

2014-05-19 20:21:42

LYNBROOK, N.Y., May 19, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX(®) in the EU, today announced that new analyses of data evaluating the use of XIAFLEX in adult men with Peyronie's disease were presented by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc. (Auxilium) at the 2014 Annual...

2014-05-19 08:27:30

Four Podium Sessions Highlight New Analyses of Data Evaluating XIAFLEX for the Treatment of Peyronie's Disease CHESTERBROOK, Pa., May 19, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that new analyses of data were presented from its clinical program and pivotal IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the Phase 3 studies that evaluated...

2014-05-12 08:30:28

CHESTERBROOK, Pa., May 12, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the UBS Healthcare Conference to be held May 19-21, 2014 at the Sheraton Times Square in New York. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 11:00 a.m. ET on...


Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related